Ginkgo Bioworks Announces Participation in Jefferies Gene Therapy/Editing Summit
Ginkgo Bioworks Inc. (NYSE: DNA) will present at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 3:00 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ginkgo Bioworks Inc. (NYSE: DNA) will present at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 3:00 p.m. Eastern Time. The company focuses on a platform for cell programming applicable to various markets, including biotechnology, pharmaceuticals, and industrial chemicals. Ginkgo has also supported COVID-19 initiatives, including vaccine optimization and testing. Investors can access the webcast and presentation replay via the company’s investor relations website.
Positive
- Participation in the Jefferies Gene Therapy/Editing Summit showcases Ginkgo's engagement in biotechnological advancements.
- The company's platform supports diverse applications in biotechnology, potentially expanding market reach.
Negative
- None.
Details
News Market Reaction – DNA
The recorded move for DNA in the trading session of this news was -7.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Oct. 20, 2021 /PRNewswire/ -- Ginkgo Bioworks Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading horizontal platform for cell programming, announced today that management is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 3:00p.m. Eastern Time.
The webcast link and replay of the presentation can be found below as well as on the company's investor relations website at https://investors.ginkgobioworks.com.
Webcasting information: https://wsw.com/webcast/jeff208/register.aspx?conf=jeff208&page=gibi&url=https://wsw.com/webcast/jeff208/gibi/1821975
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
MEDIA CONTACT:
INVESTOR CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-jefferies-gene-therapyediting-summit-301404504.html
SOURCE Ginkgo Bioworks
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.